Undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma, is a rare and aggressive subtype of soft tissue sarcomas, accounting for approximately 1% of all malignancies. It has an incidence rate of 0.08 to 1 per 100,000 individuals. Despite advances in cancer treatment, there remains a significant unmet clinical need for effective therapies for undifferentiated pleomorphic sarcoma. Current treatment options, including surgery, radiation, and chemotherapy, often fall short of preventing recurrence or managing metastasis. The increasing focus on targeted therapies and innovative approaches is expected to drive pipeline growth, offering hope for improved outcomes in this challenging malignancy.
The Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into undifferentiated pleomorphic sarcoma (UPS) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Undifferentiated Pleomorphic Sarcoma (UPS). The undifferentiated pleomorphic sarcoma (UPS) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The undifferentiated pleomorphic sarcoma (UPS) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with undifferentiated pleomorphic sarcoma (UPS) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to undifferentiated pleomorphic sarcoma (UPS).
Undifferentiated pleomorphic sarcoma (UPS) is a rare and aggressive form of soft tissue cancer, characterized by undifferentiated, abnormal cells with no identifiable origin. It commonly arises in deep tissues such as muscles or connective tissues, often linked to genetic mutations or radiation exposure. Typically presenting as a rapidly growing, painless lump, its symptoms vary depending on the tumor’s location and size.
Undifferentiated Pleomorphic Sarcoma (UPS) treatment prioritizes surgical removal of the tumor, complemented by radiation therapy to minimize recurrence risks. Chemotherapy, often with doxorubicin and ifosfamide, is utilized for advanced or metastatic cases. Innovative treatments, such as immunotherapy and targeted therapies, offer hope for resistant or recurrent tumors. Multidisciplinary strategies are essential for comprehensive care and improved outcomes.
Undifferentiated pleomorphic sarcoma (UPS) accounts for approximately 1% of all malignancies, with an incidence of 3 per 100,000 people. In the United States about 1,200 new cases are diagnosed annually, making it the most common type of soft tissue sarcoma, representing 14% of cases. Undifferentiated pleomorphic sarcoma predominantly affects individuals over 60 years old, with a higher prevalence in older populations.
This section of the report covers the analysis of undifferentiated pleomorphic sarcoma (UPS) drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total undifferentiated pleomorphic sarcoma (UPS) clinical trials.
The drug molecule categories covered under the undifferentiated pleomorphic sarcoma (UPS) pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for undifferentiated pleomorphic sarcoma (UPS).
The EMR report for the undifferentiated pleomorphic sarcoma (UPS) report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in undifferentiated pleomorphic sarcoma (UPS) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Undifferentiated Pleomorphic Sarcoma (UPS). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of undifferentiated pleomorphic sarcoma (UPS) drug candidates.
The National Cancer Institute (NCI) sponsored this Phase III trial to assess whether adding pembrolizumab to doxorubicin improves progression-free survival in undifferentiated pleomorphic sarcoma (UPS). This study involves 180 participants and is expected to conclude by June 30, 2026.
HRYZ Biotech Co. is sponsoring a Phase II study evaluating MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment of advanced soft tissue sarcoma, including undifferentiated pleomorphic sarcoma. The study aims to assess safety and efficacy, with completion expected by February 2027. The trial includes 148 participants and emphasizes innovative approaches for metastatic or unresectable sarcoma management.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Undifferentiated Pleomorphic Sarcoma (UPS) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for undifferentiated pleomorphic sarcoma (UPS). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within undifferentiated pleomorphic sarcoma (UPS) pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share